1. Introduction {#sec1-ijerph-17-04219}
===============

Measles is a highly contagious disease caused by morbillivirus. It is reported that up to 90% of susceptible persons could be infected upon contact with a patient diagnosed with measles. The measles virus can be transmitted directly through droplets and can survive up to two hours in an airspace where the patient sneezed or coughed. Moreover, an infected person can pose a risk for others four days before the onset of clinical manifestations as well as four days after symptoms disappear \[[@B1-ijerph-17-04219]\].

Measles remains one of the leading causes of child morbidity and mortality worldwide with the greatest burden borne by the youngest children \[[@B2-ijerph-17-04219],[@B3-ijerph-17-04219]\]. Therefore, the implementation of universal vaccination programs, including measles vaccinations, is a most effective tool for its prevention. Despite stepped up efforts, measles has become a public health challenge of our century. Obviously, one of the factors can be the indifference or even reluctance of parents to have their offspring vaccinated. Yet another factor not to be underestimated is the persistence of antibodies against measles that can wane with time. Therefore, a continuous follow-up of sero-immunity is conducted worldwide.

In the Czech Republic, routine vaccinations against measles were introduced with a single-dose administration in 1969 to be expanded by a two-dose schedule in 1975. The original monovalent measles vaccine was replaced by a combination vaccine against measles, mumps and rubella in 1995. The vaccination rates in children \<2 years old has ranged between 96 and 99% for the first dose, and between 84 and 99% for the second dose in the last decade \[[@B4-ijerph-17-04219]\]. The lower second-dose vaccination rate in the year 2018 was because of its intentional re-scheduling to the age of 5 years. Overall, the vaccination rate of the Czech pediatric population with at least one dose of vaccine remained high and presumably sufficient to contain the spread of the measles infection in the population. Despite this, a total of 943 cases of measles, especially in the adult population, were reported in the Czech Republic between 2017 and 2019.

As reported in many studies in the relevant literature, insufficient sero-protection in health care workers (HCWs) can pose a risk both for themselves and for patients \[[@B5-ijerph-17-04219],[@B6-ijerph-17-04219],[@B7-ijerph-17-04219]\]. Even though several observations documented \>90% seroprevalence against measles among HCWs in Italy \[[@B8-ijerph-17-04219]\], France \[[@B6-ijerph-17-04219]\], Spain \[[@B9-ijerph-17-04219]\] or Japan \[[@B10-ijerph-17-04219]\], no similar study has been conducted in the Czech Republic. Therefore, this fact served as an impetus to design and conduct a serological survey among health care workers of the Prague-based Královské Vinohrady University Hospital between May 2018 and December 2019. The primary objective was to evaluate the measles antibody status among HCWs and to assess their possible vulnerability to the disease. Moreover, we attempted to find possible factors influencing HCWs seroprevalence.

2. Materials and Methods {#sec2-ijerph-17-04219}
========================

Our prospective seroprevalence study was conducted among participants predominantly recruited from health care workers of the Faculty hospital Královské Vinohrady, in Prague. Upon receiving the consent of the would-be participants, their year of birth, weight and height, concomitant treatment and smoking status were obtained from the hospital staff database.

The participants were interviewed to determine whether or not they had been immunised or had had measles anytime in their lifetime. All declared either vaccination against measles or measles infection in childhood. As their original immunisation status could not be verified, the participants were further divided into 5-year age cohorts according to the year of birth ([Table 1](#ijerph-17-04219-t001){ref-type="table"}). The stratified cohorts were further assessed according to the history of routine vaccination against measles in the Czech Republic. The cohorts of participants born before 1966 were considered to be naturally immunised against measles while those born after 1976 were viewed as fully vaccinated with two doses of the measles vaccine. Participants born between 1966 and 1975 were either naturally immunised or vaccinated with one or two doses.

Prior to their enrolment in the study, the participants were thoroughly informed about the study and signed informed consent forms. The study protocol was approved by the Ethics Committee of the Third Faculty of Medicine, Charles University in Prague (N° 0120/17).

The current sero-immunity status of participants was assessed by serological analysis of serum samples that had been collected, stored at below −20 °C and processed in one central laboratory (Laboratory of Clinical Immunology, Královské Vinohrady University Hospital, Prague, Czech Republic). The levels of antibodies were determined using a measles IgG ELISA kit (Immunolab GmbH, Kassel, Germany). The seropositivity cut-off of \>12 AU/mL (arbitrary units per millilitre) was adopted from marginal positivity declared by the serological kit manufacturer \[[@B11-ijerph-17-04219]\].

Persistence of specific antibodies against measles was assessed both by the seropositivity rate, defined as the proportion of participants having antibody levels higher than the cut-off value, and by the geometric mean concentrations (GMCs) of measles antibodies. The demographic, behavioural and health characteristics were considered possible factors that could influence seropositivity persistence. Therefore, participants' antibody levels or seropositivity were assessed in groups categorised by these factors. The differences in the GMCs between two groups or among several groups were investigated with the parametric t-Student test or by Dunnett multiple comparisons testing following one-way analysis of variance (ANOVA) after the log-transformation of antibody levels that met the normal distribution. Categorial variables were represented by the proportion including a 95% confidence interval computed by the method of Clopper and Pearson.

The differences in seropositivity rates were statistically evaluated with Fisher's exact test, including crude odds ratios (cORs) obtained from the 2 × 2 table. The sample size was justified for logistic regression with 7 covariates---investigated predictors---that provided the adjusted odds ratios (aORs) including a 95% confidence interval (95% CI). Moreover, McFadden's R squared as well as the *p*-value of this approach were sufficient for the predictive ability of this model.

All tests were two-tailed, and the level of significance was set at 0.05. Statistical analyses and logistic regression were performed using Prism 8 (GraphPad Software, Inc., San Diego, CA, USA) and STATA version 16 software (StatCorp, Lakeway Drive, TX, USA), respectively.

3. Results {#sec3-ijerph-17-04219}
==========

Between May 2018 and December 2019, serum samples were obtained from a total of 2784 subjects with a mean age of 42 years (95% CI: 41.5--42.5 years). Although the participants were mostly women (74.7%), the age means for men and women did not differ relevantly (42.7 years for females and 40.1 years for males).

Body mass index (BMI) was not recorded in a total of 1039 subjects, i.e., 37.3% (95% CI: 35.5--39.1%), and was unavailable, especially in women (69%). The mean of BMI was significantly higher in men (26.5 kg/m^2^) than in women (25.2 kg/m^2^) but the difference did not reach clinical relevance. Almost 53% of subjects with known BMI had a normal body weight \<25 kg/m^2^, i.e., 33.2% of all enrolled participants. The distribution of participants by the BMI category is shown in [Table 1](#ijerph-17-04219-t001){ref-type="table"}.

A concomitant disease was present in 41.1% of subjects having been diagnosed most often with endocrine, nutritional and metabolic diseases (13%)---especially thyroid gland diseases or impaired lipoprotein metabolism, and cardiovascular disease (8%)---especially hypertension heart disease; or respiratory diseases (6%).

The survey participants were recruited mostly from among hospital medical staff (80.6%; broadly defined as physicians, nurses and allied health professionals) and among hospital support (laundry, cleaning, administrative, etc.) staff, with the latter group including 2.4% of foreign nationals. Information about cigarette smoking vs. non-smoking status was missing in 50% of the serologically assessed subjects.

The youngest cohort, aged 19--23 years (years of birth 1996--2000), made up 6% of the whole group. Larger cohorts comprised those born in 1976--80 and 1971--75 (participants aged 39--43 years and 44--48 years, respectively). Fully vaccinated participants were defined as those born after the year of 1975 (1510 subjects). Conversely, 600 participants with naturally acquired immunity were assigned to age cohorts \<1966.

Seropositivity against measles was detected in 93.5% of participants (95% CI: 92.6--94.4%) independently of sex, age, comorbidities, and other investigated factors ([Table 2](#ijerph-17-04219-t002){ref-type="table"}). The overall GMCs in all participants achieved 16.3 AU/mL (95% CI: 16.1--16.6 AU/mL), differing significantly between seronegative (8.5 AU/mL; 95% CI: 8.1--8.9 AU/mL) and seropositive participants (17.2 AU/mL; 95% CI: 17.0--17.4 AU/mL).

The seropositivty rate in the cohorts fully immunised with vaccine only (participants aged 19--43 years) was 93.7% (95% CI: 92.4--94.9%). Conversely, 98.0% (95% CI: 96.5--99.0%) of those naturally immunised by measles maintained their seropositivity longer than 54 years. Naturally acquired immunity against measles persisted in significantly more subjects than immunity induced by a vaccine, as demonstrated by an odds ratio of 3.29 (95% CI: 1.79--6.04). Likewise, the GMCs of measles antibodies were significantly higher in participants who had had measles (20.7 AU/mL; 95% CI: 20.1--21.3 AU/mL) than in those fully vaccinated (15.3 AU/mL; 95% CI: 15.1--15.5 AU/mL) or in those having received at least one vaccine dose (15.2 AU/mL; 95% CI: 15.0--15.4 AU/mL).

The seropositivity rate for measles did not differ between males and females although the GMCs of antibodies were significantly higher in women ([Table 2](#ijerph-17-04219-t002){ref-type="table"}). A sensitivity analysis demonstrated that the difference in the GMCs between males and females depended on of the way in which immunity is acquired. While the persistence of naturally acquired antibody levels did not differ between both sexes, vaccinated women had significantly higher GMCs of measles antibodies (16.1 AU/mL; 95% CI: 15.1--15.6 AU/mL) than vaccinated men (14.8 AU/mL; 95% CI: 14.4--15.2 AU/mL), with a *p*-value of 0.036.

The time since childhood vaccination did not influence the persistence of antibody levels as no difference in seropositivity rates between the two-dose vaccinated cohorts was found, i.e., the 5-year cohorts since the year of 1976 did not exhibit different seropositivity rates. Participants born in the 1971--1975 period, immunised predominantly with a single vaccine dose, achieved a seropositivity rate of 86.6% (95% CI: 82.8--89.9%), a value significantly lower compared with that seen in the youngest, fully vaccinated participants (i.e., 94%; 95% CI: 89.3--97.1%).

The survey did not find an impact of BMI on the persistence of seropositivity rates, which did not differ among the categories of normal weight, overweight, obesity or severe obesity. The antibody levels remained consistent across all BMI categories, as demonstrated by their similar GMCs. Moreover, sensitivity analysis confirmed consistent seropositivity rates stratified by BMI categories both in fully vaccinated participants and those naturally immunised by measles.

The persistence of seropositivity rates was similar in smokers and non-smokers irrespective of the way in which immunity had been acquired. Unknown smoking status in 1381 participants was associated with lower seropositivity rates as well as GMCs compared to those of non-smokers ([Table 2](#ijerph-17-04219-t002){ref-type="table"}). This difference was confirmed only in naturally immunised participants (aOR = 0.36; 95% CI: 0.20--0.67).

No difference in serological persistence was observed in participants with or without concomitant disease, as demonstrated by their seropositivity rates and the GMCs of measles antibodies.

Likewise, the seropositivity rates in patients with endocrine, nutritional or metabolic diseases (93.7%; 95% CI: 90.6--96.0%) and in those with cardiovascular disease (92.7%; 95% CI: 88.5--95.8%) did not differ from those of healthy participants. The sensitivity analyses showed lower seropositivity rates in naturally immunised participants with any concomitant disease (97.3%; 95% CI: 94.8--98.8%) than in those without it (98.7%; 95% CI: 96.6--99.6%) as documented by an aOR of 0.17 (95% CI: 0.03--0.88). There was no difference in the persistence of seropositivity rates or GMCs of measles antibodies between hospital medical staff and hospital support staff as defined above, as well as between foreign nationals and Czech citizens.

4. Discussion {#sec4-ijerph-17-04219}
=============

The seropositive levels of measles antibodies were observed in almost all (94%) of the survey participants, especially in HCWs, irrespective of the way in which immunity was acquired. This value is close to that reported for adult populations reported by seroprevalence studies in other countries \[[@B12-ijerph-17-04219],[@B13-ijerph-17-04219]\], in the Czech Republic in 2013 \[[@B14-ijerph-17-04219]\] as well as studies conducted in HCWs \[[@B6-ijerph-17-04219],[@B8-ijerph-17-04219],[@B9-ijerph-17-04219],[@B10-ijerph-17-04219]\]. Even though these findings are favourable, it does not mean that they will remain permanent since serological surveys conducted in Italy (in 2003--2019) showed a steep decline in seropositivity rates induced by measles vaccinations that ranged between 77.2 and 84.4% in the population younger than 50 years \[[@B15-ijerph-17-04219],[@B16-ijerph-17-04219],[@B17-ijerph-17-04219]\].

We found that the persistence of seropositivity rates was not dependent on the time since acquisition of immunity, but was determined by the way in which immunity was acquired, i.e., if the seropositivity was induced by vaccination or by childhood measles. Almost all of the participants (98%) with naturally induced antibodies against measles in childhood maintained higher antibody levels (20.7 AU/mL) than those fully or partially vaccinated (15.2 AU/mL). As no significant variation in seropositivity rates was observed among the 5-year cohorts of naturally immunised participants (range, 97--100%), naturally acquired immunity could presumably persist at least 54--70 years. This was in accordance with the rates used in modelling measles re-emergence \[[@B18-ijerph-17-04219]\].

In line with published data, long-term seropositivity induced by full vaccination was present in almost 94% participants aged 19--43 years \[[@B12-ijerph-17-04219],[@B13-ijerph-17-04219],[@B14-ijerph-17-04219]\]. This value differed significantly from that of participants born in the 1971--1975 period, the majority of whom received only a single dose of the measles vaccine (86.6%). It was consistent with a previous finding that the Czech population born between 1968 and 1978 exhibited a lower seroprevalence of 80.4% compared to a younger or older study population \[[@B14-ijerph-17-04219]\].

Our survey did not identify a single clinically relevant factor influencing the persistence of seropositivity. Even if slightly higher GMCs of antibodies were observed in women than in men, the difference, about 1 AU/mL, was non-significant. While concomitant diseases did not change the seropositivity rates in vaccinated participants, they may have contributed to a small decrease in seropositivity persistence in naturally immunised individuals. Again, it was not clear whether this finding was of clinical importance because the rate difference was less than 2%. Otherwise, the seropositivity rates in smokers, overweight and obese individuals as well as the hospital support staff did not differ significantly from those of the study population based on the way in which immunity was acquired.

It follows from the above that the persistence of antibodies against measles is determined primarily by the way in which immunity is acquired. The vaccine-induced humoral immunity, persisting 20 years or longer, was always shorter than the persistence of naturally acquired immunity, with the reduction likely occurring within the first 10--15 years after full vaccination \[[@B19-ijerph-17-04219],[@B20-ijerph-17-04219]\]. Nevertheless, the seropositive levels of antibodies were observed in more than 87% of those vaccinated with at least one dose within 48 years.

The question yet to be answered is whether or not the observed sero-persistence is sufficient to counter measles resurgence. Unfortunately, the results of our study are not able to provide the answer since further immune mechanisms and factors such as complement, immunological memory, and cellular immunity play an important role in one's protection \[[@B21-ijerph-17-04219]\]. Furthermore, the threshold of enzyme immunoassay for determining protective antibody levels has not been yet standardised \[[@B22-ijerph-17-04219],[@B23-ijerph-17-04219]\].

Furthermore, our results may have been biased by indirect booster immunisation due to an exposure to measles, especially in those born in the 1970--1985 period, which we hope is not the case. Even if the main study population was that of hospital medical staff, less than 20% of participants were enrolled from among hospital support staff. A selection bias with this small subgroup could not have a major impact on our results, as demonstrated by the similar seropositive rates. A potential limitation of the present serological survey was the lack of immunisation status verification---our inability to verify the immunization status of our study participants, which was only self-reported.

However, we are not convinced that fully vaccinated or naturally immunised health care workers need to be systematically revaccinated by one or more vaccine doses in adult age. Moreover, the outcome of our study in HCWs was similar to that of another survey conducted in the Czech general population in 2013, making it unlikely that this specific subgroup of individuals would be at higher risk than the rest of the population.

5. Conclusions {#sec5-ijerph-17-04219}
==============

A full measles vaccination in childhood was capable of inducing sufficient antibody levels that persisted at seropositive values that most of the health care workers acquired over a period of 43 years. As expected, the levels of vaccine-induced antibodies were lower than those acquired naturally. Despite this, we recommend that, instead of systematic revaccination or the serological monitoring of antibodies, targeted immunisation of at-risk health care workers with incomplete vaccinations or with missing information about their sero-immunity status could prove a quick, highly effective and reasonable tool in the event of a measles outbreak.
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###### 

Number and proportion of participants (including the 95% confidence intervals) stratified by assessed demographic, behavioural and health factors.

  Stratification                     All                 Women                                   
  --------------------- ------------ ------------------- ------------------- ------------------- -------------------
  Participants                       2784                                    2080                74.7 (73.1--76.3)
  Age cohort            1996--2000   168                 6.0 (5.2--7.0)      115                 68.5 (60.8--75.4)
                        1991--1995   354                 12.7 (11.5--14.0)   229                 64.7 (59.5--69.7)
  1986--1990            298          10.7 (9.6--11.9)    206                 69.1 (63.5--74.3)   
  1981--1985            299          10.7 (9.6--11.9)    217                 72.6 (67.1--77.6)   
  1976--1980            391          14.0 (12.8--15.4)   308                 78.8 (74.4--82.7)   
  1971--1975            389          14.0 (12.7--15.3)   300                 77.1 (72.6--81.2)   
  1966--1970            285          10.2 (9.1--11.4)    236                 82.8 (77.9--87.0)   
  1961--1965            242          8.7 (7.7--9.8)      202                 83.5 (78.2--87.9)   
  1956--1960            207          7.4 (6.5--8.5)      167                 80.7 (74.6--85.8)   
  1951--1955            83           3.0 (2.4--3.7)      66                  79.5 (69.2--87.6)   
  \<1950                68           2.4 (1.9--3.1)      34                  50.0 (37.6--62.4)   
  BMI ^2^ (kg/m^2^)     \<25         924                 33.2 (31.4--35.0)   760                 82.3 (79.6--84.7)
                        25--\<30     512                 18.4 (17.0--19.9)   360                 70.3 (66.1--74.2)
  30--\<35              246          8.8 (7.8--10.0)     195                 79.3 (73.7--84.2)   
  ≥35                   63           2.3 (1.7--2.9)      45                  71.4 (58.7--82.1)   
  Unknown               1039         37.3 (35.5--39.1)   720                 69.3 (66.4--72.1)   
  Concomitant disease                1144                41.1 (39.3--42.9)   940                 82.2 (79.8--84.3)
  Health care worker                 2243                80.6 (79.0--82.0)   1699                75.7 (73.9--77.5)
  Foreign national                   68                  2.4 (1.9--3.1)      36                  52.9 (40.4--65.2)
  Smoker                No           882                 31.7 (30.0--33.4)   709                 80.4 (77.6--83.0)
                        Yes          521                 18.7 (17.3--20.2)   410                 78.7 (74.9--82.1)
                        Unknown      1381                49.6 (47.7--51.5)   961                 69.6 (67.1--72.0)

^1^ N: number of participants; ^2^ BMI: body mass index; ^3^ CI: confidence intervals.
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###### 

Persistence of seropositivity against measles and geometric mean concentrations (GMCs) of measles antibodies, crude and mutually adjusted odds ratios (cORs, aORs) including the 95% confidence interval.

  Predictors                         N ^1^   n ^2^   Seropositivity %      cOR ^3^                 aOR ^4^ (95% CI)        GMC ^5^ (95%CI); AU/mL ^6^
  --------------------- ------------ ------- ------- --------------------- ----------------------- ----------------------- ----------------------------
  Total                              2784    2604    93.5 (92.6--94.4)                                                     16.3 (16.1--16.6)
  Sex                   Male         704     655     93.0 (90.9--94.8)     1                       1                       15.7 (15.3--16.1)
                        Female       2080    1949    93.7 (92.6--94.7)     1.11 (0.79--1.56)       1.13 (0.80--1.62)       16.6 (16.3--16.8) ^†^
  Age cohort            1996--2000   168     158     94.0 (89.3--97.1)     1                       1                       14.5 (13.9--15.2)
                        1991--1995   354     337     95.2 (92.4--97.2)     1.25 (0.56--2.80)       1.17 (0.52--2.65)       15.9 (15.4--16.5)
                        1986--1990   298     285     95.6 (92.7--97.7)     1.39 (0.59--3.24)       1.29 (0.53--3.13)       16.0 (15.4--16.6)
                        1981--1985   299     271     90.6 (86.8--93.7)     0.61 (0.29--1.29)       0.55 (0.25--1.21)       14.5 (14.0--15.0)
                        1976--1980   391     364     93.1 (90.1--95.4)     0.85 (0.40--1.80)       0.78 (0.35--1.72)       15.0 (14.6--15.5)
                        1971--1975   389     337     86.6 (82.8--89.9)     0.41 (0.20--0.83) \*    0.37 (0.18--0.78) \*    14.7 (14.2--15.2)
                        1966--1970   285     264     92.6 (89.0--95.4)     0.80 (0.37--1.73)       0.75 (0.33--1.71)       16.6 (16.0--17.4) ^†^
                        1961--1965   242     235     97.1 (94.1--98.8)     2.12 (0.79--5.70)       1.94 (0.70--5.45)       20.9 (19.8--22.0) ^‡^
                        1956--1960   207     202     97.6 (94.5--99.2)     2.56 (0.86--7.63)       2.43 (0.79--7.49)       20.8 (19.8--21.9) ^‡^
                        1951--1955   83      83      100.0 (95.7--100.0)   x                       x                       20.8 (19.5--22.3) ^‡^
                        \<1950       68      68      100.0 (94.7--100.0)   x                       x                       19.2 (18.0--20.5) ^‡^
  BMI ^7^ (kg/m2)       \<25         924     863     93.4 (91.6--94.9)     1                       1                       16.3 (16.0--16.7)
                        25--\<30     512     478     93.4 (90.8--95.4)     0.99 (0.64--1.53)       0.98 (0.63--1.53)       16.6 (16.1--17.2)
                        30--\<35     246     228     92.7 (88.7--95.6)     0.90 (0.52--1.55)       0.88 (0.50--1.53)       16.6 (15.9--17.4)
                        ≥35          63      60      95.2 (86.7--99.0)     1.41 (0.43--4.64)       1.41 (0.42--4.75)       16.1 (15.0--17.3)
                        Unknown      1039    975     93.8 (92.2--95.2)     1.08 (0.75--1.55)       1.56 (0.99--2.47)       16.2 (15.8--16.5)
  Concomitant disease   No           1640    1539    93.8 (92.6--95.0)     1                       1                       16.2 (16.0--16.5)
                        Yes          1144    1065    93.1 (91.5--94.5)     0.88 (0.65--1.20)       0.83 (0.59--1.16)       16.5 (16.1--16.9)
  Health care worker    No           541     501     92.6 (90.1--94.7)     1                       1                       15.9 (15.5--16.4)
                        Yes          2243    2,103   93.8 (92.7--94.7)     1.20 (0.83--1.73)       1.27 (0.84--1.92)       16.4 (16.2--16.7)
  Foreign national      No           2716    2540    93.5 (92.5--94.4)     1                       1                       16.3 (16.1--16.6)
                        Yes          68      64      94.1 (85.6--98.4)     1.11 (0.40--3.08)       1.12 (0.37--3.43)       16.7 (15.3--18.3)
  Smoker                No           882     838     95.0 (93.4--96.4)     1                       1                       16.8 (16.4--17.2)
                        Yes          521     490     94.0 (91.7--95.9)     0.83 (0.52--1.33)       0.83 (0.51--1.33)       17.0 (16.5--17.5)
                        Unknown      1381    1276    92.4 (90.9--93.7)     0.64 (0.44--0.92) ^‡^   0.48 (0.31--0.72) ^‡^   15.9 (15.6--16.2) ^†^

^1^ N: total number of factor--stratified participants; ^2^ n: total number of seropositive participants; ^3^ cOR: crude odds ratio; ^4^ aOR: mutually adjusted odds ratio; ^5^ GMC: geometric mean concentration; ^6^ AU/mL: arbitrary units per millilitre; ^7^ BMI: body mass index; \* *p* \< 0.05; ^†^ *p* \< 0.001; ^‡^ *p* \< 0.0001.
